Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04903717 · ClinicalTrials.gov registry record · NA
Pragmatic Trial Of Alerts for Use of Mineralocorticoid Receptor Antagonists
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 1,210
- Enrollment target
NCT04903717 is a NA study that has completed, run by Yale University. The registered enrollment target is 1,210 participants.
The verdict
NCT04903717, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,210 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine if a best practice alert (BPA) system that prompts providers to consider the addition of a mineralocorticoid receptor antagonist (MRA) in eligible patients with heart failure with reduced ejection fraction (HFrEF) will result in increased prescription of this guideline-recommended therapy. The system will also inform providers about FDA-approved potassium binders for the treatment of hyperkalemia if elevated potassium is a barrier for MRA use and will provide educational information on the evidence for MRA therapy in these patients.
Interventions
- BEHAVIORAL Best Practice Alert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,210 participants |
| Start Date | 2021-11-03 |
| Est. Completion | 2024-02-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04903717
The ClinicalTrials.gov registry entry for NCT04903717 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Best Practice Alert is the first listed.
NCT04903717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04903717 about?
NCT04903717 is a clinical study titled "Pragmatic Trial Of Alerts for Use of Mineralocorticoid Receptor Antagonists". The primary objective of this study is to determine if a best practice alert (BPA) system that prompts providers to consider the addition of a mineralocorticoid receptor antagonist (MRA) in eligible patients with heart failure with reduced ejection fraction (HFrEF) will result in increased prescript...
What is the current status of trial NCT04903717?
This trial is currently completed. It is a NA study. The enrollment target is 1,210 participants. The study started on 2021-11-03. Estimated completion is 2024-02-06.
What interventions are being tested in trial NCT04903717?
The interventions under investigation include: Best Practice Alert (BEHAVIORAL).
Who is sponsoring clinical trial NCT04903717?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.